Elevance Health, Inc. ELV SPXR3KPHARMA
Company Overview
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Why Investors Should Care
Trades at a P/E of 19.5, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $199.12B (+12.6% YoY); net profit $5.66B.
- Trailing 12 Months Year-on-year growth — revenue +1.4%, earnings -13.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR 3.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.19% |
| 1 Year: | 1.40% |
Compounded Profit Growth
| 5 Years: | 3.14% |
| 1 Year: | -13.10% |
Stock Price Performance
| 1 Year: | +52.56% |
| 6 Months: | +28.69% |
| 3 Months: | +16.78% |
| 1 Month: | +10.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.38 · Neutral
P/E of 19.48 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELV Elevance Health, Inc. SPXR3KPHARMA | 439.95 | 19.48 | $95.41B | 1.72% | 9.37% | 11.13% | 7.19% | 3.14% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.19B | 20.29B | 21.46B | 21.40B | 21.71B | 22.52B | 22.41B | 22.43B | 22.68B | 22.54B | 22.94B | 23.25B | 23.37B | 24.67B | 25.47B | 26.67B | 27.41B | 29.62B | 29.26B | 31.16B | 31.82B | 32.38B | 33.85B | 35.82B | 38.09B | 38.63B | 39.94B | 42.17B | 43.67B | 42.85B | 42.58B | 43.89B | - | - | 48.89B | 49.78B | 50.71B | 49.75B | 50.18B | 50.47B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | 1.57B | 1.50B | 1.08B | - | 1.59B | 1.23B | 982.00M | - | 1.87B | 1.56B | 1.25B | - | 1.94B | 1.43B | 1.53B | - | 2.19B | 3.36B | 201.00M | - | 2.16B | 2.08B | 2.06B | 2.43B | 2.35B | 2.25B | 2.83B | 2.63B | 1.76B | 3.02B | 2.77B | - | - | 3.14B | 2.63B | 1.76B | 581.00M | 2.66B | 2.30B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 344.00M | 341.00M | 351.00M | 366.00M | 357.00M | 364.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.80B | 2.29B | 1.41B | 215.00M | 2.30B | 1.94B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 613.00M | 548.00M | 219.00M | -331.00M | 544.00M | 483.00M |
| Net Income | 180.90M | 703.00M | 780.60M | 617.80M | 368.40M | 1.01B | 855.00M | 747.00M | 1.23B | 1.31B | 1.05B | 960.00M | 424.00M | 1.55B | 1.14B | 1.18B | 934.00M | 1.52B | 2.28B | 222.00M | 551.00M | 1.67B | 1.79B | 1.51B | 1.79B | 1.64B | 1.60B | 1.99B | 1.85B | 1.29B | 2.25B | 2.30B | - | - | 2.18B | 1.74B | 1.19B | 547.00M | 1.76B | 1.46B |
| Diluted EPS | 0.68 | 2.63 | 2.91 | 2.30 | 1.37 | 3.73 | 3.16 | 2.80 | 4.67 | 4.99 | 3.98 | 3.62 | 1.61 | 5.91 | 4.36 | 4.55 | 3.62 | 5.94 | 8.91 | 0.87 | 2.19 | 6.71 | 7.25 | 6.13 | 7.32 | 6.73 | 6.62 | 8.30 | 7.79 | 5.45 | 9.59 | 9.85 | - | - | 9.61 | 7.72 | 5.32 | 2.47 | 8.00 | 6.71 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.17B | 61.25B | 64.94B | 58.70B | 60.71B | 61.50B | 71.02B | 73.87B | 79.16B | 84.86B | 90.04B | 92.11B | 104.21B | 121.87B | - | 156.59B | 171.34B | 176.81B | 199.12B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | 4.35B | 4.18B | 4.08B | 3.78B | 3.62B | 4.00B | 4.42B | 4.75B | 4.80B | 4.17B | 5.43B | 6.00B | 6.36B | - | 8.45B | 8.74B | 9.09B | 8.11B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 851.00M | 1.03B | 1.19B | 1.40B |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.60B | 7.71B | 7.90B | 6.71B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 3.35B | 2.49B | 4.75B | 2.89B | 2.65B | 2.66B | 2.49B | 2.57B | 2.56B | 2.47B | 3.84B | 3.75B | 4.81B | 4.57B | - | 5.89B | 5.99B | 5.98B | 5.66B |
| Diluted EPS | 5.56 | 4.76 | 9.88 | 6.94 | 7.25 | 8.18 | 8.20 | 8.99 | 9.38 | 9.21 | 14.35 | 14.19 | 18.47 | 17.98 | - | 24.81 | 25.22 | 25.68 | 25.21 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 48.40B | 52.13B | 50.17B | 52.16B | 58.96B | 59.57B | 61.68B | 61.72B | 65.08B | 70.54B | 71.57B | 77.45B | 86.61B | 97.46B | 102.75B | 108.93B | 116.89B | 121.49B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cash & Equivalents | 2.60B | 2.77B | 2.18B | 4.82B | 1.79B | 2.20B | 2.48B | 1.58B | 2.15B | 2.11B | 4.08B | 3.61B | 3.93B | 4.94B | 5.74B | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.08B | 7.90B | 8.01B | 10.07B |
| Total Liabilities | - | - | 26.97B | 27.26B | 26.35B | 28.88B | 35.15B | 34.81B | 37.42B | 38.67B | 39.98B | 44.04B | 43.03B | 45.73B | 53.42B | 61.33B | 66.42B | 69.52B | 75.46B | 77.47B |
| Current Liabilities | - | - | 15.02B | 14.67B | 14.01B | 15.90B | 15.99B | 16.35B | 18.75B | 19.09B | 21.29B | 23.36B | 21.96B | 23.53B | 29.45B | 34.88B | - | - | - | - |
| Long Term Debt | - | - | 7.83B | 8.34B | 8.15B | 8.47B | 14.17B | 13.57B | 14.02B | 15.32B | 14.36B | 17.38B | 17.22B | 17.79B | 19.34B | 21.16B | 22.35B | 23.25B | 29.22B | 30.80B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.11B | 25.12B | 31.23B | 32.05B |
| Total Equity | 24.58B | 22.99B | 21.43B | 24.86B | 23.81B | 23.29B | 23.80B | 24.77B | 24.25B | 23.05B | 25.10B | 26.50B | 28.54B | 31.73B | 33.20B | 36.06B | 36.24B | 39.31B | 41.31B | 43.88B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 237.96M | 233.07M | 227.48M | 220.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.34B | 2.54B | 3.04B | 1.42B | 3.37B | 2.74B | 3.05B | 3.37B | 4.21B | 3.27B | 4.18B | 3.83B | 6.06B | 10.69B | 8.36B | 8.40B | 8.06B | 5.81B | 4.29B |
| Investing Cash Flow | -768.90M | 616.20M | 3.00B | -1.27B | -942.00M | -4.55B | -2.23B | -974.90M | -1.15B | -514.00M | -5.08B | -1.26B | -2.79B | -7.32B | -9.64B | -4.56B | -5.57B | -5.17B | -1.34B |
| Financing Cash Flow | -3.41B | -3.74B | -3.40B | -3.17B | -2.02B | 2.09B | -1.72B | -1.82B | -3.09B | -799.00M | 427.00M | -2.24B | -2.27B | -2.57B | 423.00M | -1.32B | -3.35B | 1.19B | -1.74B |
| Capital Expenditure | -322.00M | -345.60M | -378.40M | -451.40M | -519.50M | -544.90M | -646.50M | -714.60M | -638.20M | -584.00M | -791.00M | -1.21B | -1.08B | -1.02B | -1.09B | -1.15B | -1.30B | -1.26B | -1.12B |
| Free Cash Flow | 4.02B | 2.19B | 2.66B | 965.30M | 2.85B | 2.20B | 2.41B | 2.65B | 3.57B | 2.69B | 3.39B | 2.62B | 4.98B | 9.67B | 7.28B | 7.25B | 6.76B | 4.55B | 3.17B |
| Share Buybacks | 6.15B | 3.28B | 2.64B | 4.36B | 3.04B | 2.50B | 1.62B | 3.00B | 1.52B | 0 | 2.00B | 1.69B | 1.70B | 2.70B | 1.90B | 2.32B | 2.68B | 2.90B | 2.60B |
| Dividends Paid | - | - | - | 0 | 357.80M | 367.10M | 448.00M | 480.70M | 656.60M | 684.00M | 705.00M | 776.00M | 818.00M | 954.00M | 1.10B | 1.23B | 1.40B | 1.51B | 1.53B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | 7.1% | 6.4% | 6.9% | 6.2% | 5.9% | 5.6% | 6.0% | 6.0% | 5.7% | 4.6% | 5.9% | 5.8% | 5.2% | - | 5.4% | 5.1% | 5.1% | 4.1% |
| Net Margin % | 5.5% | 4.1% | 7.3% | 4.9% | 4.4% | 4.3% | 3.5% | 3.5% | 3.2% | 2.9% | 4.3% | 4.1% | 4.6% | 3.8% | - | 3.8% | 3.5% | 3.4% | 2.8% |
| ROE % | 14.6% | 11.6% | 19.1% | 12.1% | 11.4% | 11.2% | 10.1% | 10.6% | 11.1% | 9.8% | 14.5% | 13.1% | 15.2% | 13.8% | - | 16.3% | 15.2% | 14.5% | 12.9% |
| ROCE % | - | 13.0% | 11.2% | 11.3% | 10.4% | 8.4% | 9.3% | 10.3% | 11.2% | 11.0% | 8.8% | 10.9% | 11.1% | 11.1% | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.76% | 18.99M | $7.84B |
| 2 | Vanguard Capital Management LLC | 6.48% | 14.06M | $5.80B |
| 3 | State Street Corporation | 4.81% | 10.43M | $4.30B |
| 4 | Wellington Management Group, LLP | 4.25% | 9.21M | $3.80B |
| 5 | Vanguard Portfolio Management LLC | 2.87% | 6.21M | $2.56B |
| 6 | Sanders Capital, LLC | 2.69% | 5.83M | $2.40B |
| 7 | Geode Capital Management, LLC | 2.38% | 5.17M | $2.13B |
| 8 | Harris Associates L.P. | 2.27% | 4.92M | $2.03B |
| 9 | Artisan Partners Limited Partnership | 2.11% | 4.58M | $1.89B |
| 10 | Invesco Ltd. | 1.95% | 4.23M | $1.75B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELV
Elevance Health (ELV) Stock Rallies As Q3 Results Tighten Margin Focus - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQZC1GUTZIYXFKZkJ0RDIwUXlEUi1wa2FxWUJlWS1KMzFCS0pKUnlIaTVSODlOZE5YMkxDMlEtU3NEVzUxWWhWQlhIWkk4QnpMcjluMHQ2TTdrWmVaRnBOUDE2azFoLW5odlB3XzZXT0RReVNSWHhrUXFuN0YyaV9DcDA2UWRsNDd3TThUSW…
Elevance Health (NYSE:ELV) Shares Rise as Q3 Earnings Beat and Raised Outlook Offset Inline Revenue - ChartMill
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNZ0lrMFhuTjV6VW5ndUxGeEpjLWVnTUhSVm5TSU03cGdxeXBvaWtFRzFId1BBRHdkZ2FTMzduVmdCYWRvTWFPTW4wYjA4Z0p0MjVUejFsdkticVplSjRMdDdQamU3V3RSdmF6UTVteVBHbkZ0em1kUGlZeC14dFRmTlpSMjVxLWdFTDlRZG…
ELV vs. RVTY: Which Stock Is the Better Value Option? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOSkdZbFBrc193TTd4eEdKeUdVcmRQUmdDVGdOS3NPbnppMmVwWmJiWklQR3hGdDVzRENic201bVhOeWtBbjRFaVNqR3dPR2NfaVNDMWhaaHBHNXpRb3REcGdrUTBaVUx0NVlDNEV4Wl93bDU5V1pKUzZtOFJZbXhxVWpDaC1iZ2dfUTdsOD…
ELV 261120 600.00P (ELV261120P600000) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1IUlNBdTRud2tUaTR0bklORVQyVmJtQ1VjVjVjak1aazlVU2k0LUxWeXVBbnBzTmV4SVhMZ1VqdjJobEVvakJGVC02SzZFeXcwMVRVOVZNMzJhV0hKejM0?oc=5" target="_blank">ELV 261120 600.00P (ELV261120P600000) S…
Elevance Health: Better Results, But Not Enough To Buy (NYSE:ELV) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQbGJkb01aaS11akkzTXgyb3owZDN1dThBZ29tTWE2ek53YWZseWs5R0pnQWJtZFZKMG1tRy10cG82QnQ3OVpKdHJwMFJUbWw3SFNqQVM5bV9wU0VpenN5dVFwU3l0X1FURGZMaVpPVV9oWWhEV1dTRjF2VDFZUVg2M2hoZ3QyVktGZ2NnQ1…
Issuance/retirement of stock (net) of Elevance Health, Inc. – NYSE:ELV - TradingView
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQV3FKS2RjOVpBT0k1Y3NaM0VRNGViQlhVUVd1VTR2Tkh0VFpxd0VDeC00MEN6TG9qX2hMWF9LeEhMSVdOUzBwakRZM2N2M0wydGZMY3V0VzZmWEVTRXlxcWJld01hSGoyTFU1Nnc0NEhUbC1OeHdlTWdqRzVZNW1Fcmp3Z29tSDduVW15am…
ELV — Frequently Asked Questions
What is the current share price of Elevance Health, Inc. (ELV)?
As of 2026-10-23 16:27 PDT, Elevance Health, Inc. (ELV) trades at $439.95 on NYSE. Its 52-week range is $276.68 to $445.28.
What is the market capitalisation of ELV?
Elevance Health, Inc. (ELV) has a market capitalisation of $95.41B on NYSE.
What is the P/E ratio of ELV?
ELV trades at a trailing price-to-earnings (P/E) ratio of 19.48. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.99.
Does ELV pay a dividend?
Elevance Health, Inc. (ELV) currently offers a dividend yield of 1.72%.
What is the return on equity (ROE) of ELV?
ELV has a return on equity (ROE) of 11.13%. Its return on capital employed (ROCE) is 9.37%.
Is ELV a good stock to buy?
This page provides a data-driven analysis of Elevance Health, Inc. (ELV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.